Clinical Summary Of Neoadjuvant Chemotherapy In Patients With Advanced Epithelial Ovarian Cancer

Objective: This study was performed to evaluate the possibility of primary optimal surgery and the efficacy of neoadjuvant chemotherapy (NAC) in patients with advanced epithelial ovarian cancer.Methods: From 1996.1-2008.12, 92 patients with histologically confirmed epithelial ovarian cancer at International Federation of Gyneco- logy and Obstetrics stages IIIc-IV were retrospectively reviewed.18 patients were treated with neoadjuvant chemotherapy and interval debulking surgery (PCS).74 patients underwent primary debuking surgery followed by plati- num-based chemotherapy(NAC).Results: Suboptimal debulking was statistically associated with those of having complications (P=0.022),cavity hydrops( P=0.011) ,CA125>1000U/L(P=0.03),patients at stage IV had a suboptimal debulking surgery compared toâ…¢C(P=0.01) ,but this difference only present in those who had a liver or pulmonary metastasis(P=0.031).The total effective rate of NAC is 66.7%.The tumor resection rate in the patient group receiving neoadjuvant chemotherapy was significantly higher (P=0.022) than that of primary debuking surgery group;NAC shorten the remaining time of drain pipe(P=0.011),decrease ascites(P=0.05),reduce blood loss(P=0.048).But the time spent in surgery,blood transfusion,require-ments hospital stays, disease- free and overall survival rates had no significant diffrience(P>0.05).Conclusions:This study demonstrates that people who had compli- cations, cavity hydrops, CA125>1000U/L,FIGO stage IV with liver or pulmonary metastasis can be chosen for NAC;NAC provided a higher rate of optimum cytoreduction and reduced intraoperative and postoperative com- plications;NAC may be improve the prognosis of the patients who suffered the advanced ovarian cancer.